Please try another search
For the nine months ended 30 June 2017, Aeolus Pharmaceuticals, Inc. revenues decreased 85% to $225K. Net loss applicable to common stockholders decreased 39% to $3.1M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Research and development - other decrease of 46% to $1M (expense), Interest expense decrease from $285K (expense) to $0K.
Period Ending: | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 |
---|---|---|---|---|
Total Revenue | 0.01 | 0.13 | 0.08 | 0.55 |
Gross Profit | ||||
Operating Income | -0.95 | -1.03 | -1.09 | -1.02 |
Net Income | -0.95 | -1.03 | -1.09 | -1.02 |
Period Ending: | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 |
---|---|---|---|---|
Total Assets | 0.79 | 1.76 | 2.65 | 4.17 |
Total Liabilities | 0.59 | 0.64 | 0.51 | 0.97 |
Total Equity | 0.21 | 1.13 | 2.13 | 3.19 |
Period Ending: | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 |
---|---|---|---|---|
Period Length: | 9 Months | 6 Months | 3 Months | 12 Months |
Cash From Operating Activities | -2.75 | -2.17 | -1.26 | -3.11 |
Cash From Investing Activities | ||||
Cash From Financing Activities | 0 | 0 | 0 | 6.17 |
Net Change in Cash | -2.75 | -2.17 | -1.26 | 3.06 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review